ResMed Inc. income statement & cash flow
In the fiscal year ended Jun 30, 2026, ResMed Inc. reported net income of $1.52B on revenue of $5.65B. Operating cash flow was $1.81B and capital expenditures were $156.28M, leaving $1.65B of free cash flow (operating cash flow minus capital expenditures).
Income statement and cash flow summary
| Fiscal year ended | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.07B | $2.34B | $2.61B | $2.96B | $3.20B | $3.58B | $4.22B | $4.69B | $5.15B | $5.65B |
| Gross profit | $1.20B | $1.33B | $1.49B | $1.72B | $1.84B | $2.02B | $2.36B | $2.66B | $3.05B | $3.45B |
| Operating income | $425.80M | $541.83M | $579.26M | $809.66M | $903.68M | $1.00B | $1.13B | $1.32B | $1.69B | $1.89B |
| Net income | $342.28M | $315.59M | $404.59M | $621.67M | $474.50M | $779.44M | $897.56M | $1.02B | $1.40B | $1.52B |
| Diluted EPS | $2.40 | $2.19 | $2.80 | $4.27 | $3.24 | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 |
| Operating cash flow | $414.05M | $505.03M | $459.05M | $802.25M | $736.72M | $351.15M | $693.30M | $1.40B | $1.75B | $1.81B |
| Capital expenditures | $62.22M | $62.58M | $68.71M | $95.33M | $102.71M | $134.84M | $119.67M | $99.46M | $89.86M | $156.28M |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Jun 2026 | 61.1% | 33.4% | 26.9% |
| Jun 2025 | 59.4% | 32.7% | 27.2% |
| Jun 2024 | 56.7% | 28.2% | 21.8% |
| Jun 2023 | 55.8% | 26.8% | 21.3% |
| Jun 2022 | 56.6% | 28.0% | 21.8% |
Source: SEC EDGAR XBRL company facts for CIK 943819 (raw data). Most recent filing in this dataset: 10-Q filed Oct 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.